文献速递血液净化与透析水电解质与酸碱

依特卡肽对血液透析患者不同严重程度继发性甲状旁腺功能亢进均有效

Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients.
PubMed 文献 · Kidney Int Rep · 2019-04-16

该分析基于两项平行、3期、随机、安慰剂对照、26周试验,纳入1023例维持性血液透析的继发性甲状旁腺功能亢进成人患者,按基线完整甲状旁腺激素水平分层评估依特卡肽的疗效。结果显示依特卡肽在各基线分层中降低完整甲状旁腺激素的百分比相似,但在最低基线分层中达标比例最高且剂量需求最小。

要点

  • 依特卡肽在各基线iPTH分层中降低iPTH的百分比相似。
  • 最低基线iPTH分层中达标比例最高且依特卡肽剂量需求最小。
  • 依特卡肽在各分层中均降低血钙和血磷,最高基线iPTH者降幅最明显。

核心结论

  • 依特卡肽能有效降低血清完整甲状旁腺激素、钙和磷,与继发性甲状旁腺功能亢进的严重程度无关。
  • 在疾病严重程度最低的患者中起始依特卡肽时,达标能力最强且剂量需求最小。

研究设计与样本

  • 分析了两项平行、3期、随机、安慰剂对照、26周试验的数据。
  • 纳入1023例年龄≥18岁、接受维持性血液透析的继发性甲状旁腺功能亢进患者。
  • 按基线完整甲状旁腺激素分层:<600、600-1000和>1000 ng/l。

主要发现

  • 依特卡肽在各基线分层中降低血清完整甲状旁腺激素的百分比相似。
  • 依特卡肽组中各分层达到完整甲状旁腺激素降低>30%的比例相似。
  • 安慰剂组各分层中甲状旁腺激素轻度升高,最低分层最明显。
  • 依特卡肽治疗患者各分层血清钙和磷均下降,最高基线甲状旁腺激素者降幅最明显。
  • 达到甲状旁腺激素、磷及两者联合靶目标的比例在最低基线甲状旁腺激素分层最高,且该分层依特卡肽剂量需求最低。

关键数值与推荐

  • 基线完整甲状旁腺激素分层:<600、600-1000和>1000 ng/l。
  • 评估指标包括完整甲状旁腺激素平均百分比变化、钙和磷变化、达到血清完整甲状旁腺激素≤300 ng/l、磷<1.78 mmol/l及两者联合靶目标。

临床怎么用

  • 依特卡肽可考虑用于各严重程度的继发性甲状旁腺功能亢进血液透析患者。
  • 在疾病严重程度较低时起始依特卡肽可能更易达标且剂量需求更低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Calcimimetics improve parameters of secondary hyperparathyroidism (sHPT) but are mostly initiated when patients have severe disease, potentially limiting effectiveness. We evaluated the effects of etelcalcetide on lowering intact parathyroid hormone, calcium, and phosphate at different disease severity levels. METHODS: This analysis examined data from 2 parallel, phase 3, randomized, placebo-controlled, 26-week trials conducted in 1023 adult (≥18 years old) patients with sHPT on maintenance hemodialysis. Etelcalcetide effects by baseline intact parathyroid hormone stratum (<600, 600-1000, and >1000 ng/l) on mean percentage change in intact parathyroid hormone; changes in calcium and phosphate; and achieving serum intact parathyroid hormone ≤300 ng/l, phosphate <1.78 mmol/l, and both combined, were assessed. RESULTS: Etelcalcetide reduced serum intact parathyroid hormone by a similar percentage across baseline strata. A similar proportion achieved >30% intact parathyroid hormone reduction across strata for the etelcalcetide arms. Parathyroid hormone increased modestly in each placebo-group stratum, most prominently in the lowest stratum. Serum calcium and phosphate concentrations decreased across strata in etelcalcetide-treated patients, with the most pronounced reductions in patients with highest baseline parathyroid hormone. However, the proportion of patients achieving parathyroid hormone, phosphate, and both targets was highest in the lowest baseline parathyroid hormone stratum, where etelcalcetide dose requirements were lowest. Etelcalcetide dose requirement was lowest among patients in the lowest intact parathyroid hormone stratum. CONCLUSION: Etelcalcetide effectively lowered serum intact parathyroid hormone, calcium, and phosphate, irrespective of the severity of secondary hyperparathyroidism. The ability to achieve target goals was greatest, and dose requirement smallest, when etelcalcetide was initiated among patients with the lowest level of disease severity.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Cunningham J, Block GA, Chertow GM, et al. Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients. Kidney Int Rep. 2019. PMID: 31317120. doi:10.1016/j.ekir.2019.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。